Clinical Trials Logo

Abnormal Karyotype clinical trials

View clinical trials related to Abnormal Karyotype.

Filter by:

NCT ID: NCT02915276 Not yet recruiting - Abnormal Karyotype Clinical Trials

The Effectiveness of Blastocentesis Versus Trophectoderm Biopsy

Start date: October 2016
Phase: Phase 0
Study type: Interventional

For the purpose of this study, the investigators will perform the removal of trophectoderm (TE) the cells as required for the purpose of pre-implantation genetic screening, in order to perform the genetic analysis. Additionally, the investigators will remove the blastocoelic fluid (BF) and perform additional genetic analysis on the embryo in order to determine the agreement of the genetics results between TE cells and BF.

NCT ID: NCT01670084 Withdrawn - Clinical trials for Blastic Phase Chronic Myelogenous Leukemia

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Start date: December 2012
Phase: Phase 2
Study type: Interventional

In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD is a combination of cyclophosphamide, mesna, vincristine (vincristine sulfate), doxorubicin (doxorubicin hydrochloride), dexamethasone, methotrexate, cytarabine, and rituximab (only for patients with cluster of differentiation [CD]20 positive disease). Researchers don't know all the ways that this drug may affect people

NCT ID: NCT01549548 No longer available - Clinical trials for Chronic Myeloid Leukemia

Compassionate Use Ponatinib

Start date: n/a
Phase: N/A
Study type: Expanded Access

The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.

NCT ID: NCT01503502 Active, not recruiting - Clinical trials for Myelogenous Leukemia, Chronic

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Start date: August 2011
Phase: Phase 2
Study type: Interventional

It is an open-label, randomized, multi-center study. The efficacy and safety of two flumatinib doses, 400 mg once daily and 600 mg once daily, will be compared with imatinib 400 mg once daily in newly diagnosed (within 6 months) patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

NCT ID: NCT01383447 Terminated - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of entinostat when given together with imatinib mesylate and to see how well it works in treating patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Entinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT01374139 Completed - Clinical trials for Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)

Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to demonstrate the bioequivalence of the clinical tablet formulation (100 mg x 5) to the clinical capsule formulation (100 mg x 5) in healthy subjects under fed condition (Cohort 1) and to investigate the effect of a high-fat meal on the pharmacokinetics of bosutinib after administration of the proposed commercial tablet formulation (100 mg x 4) in healthy subjects (Cohort 2).

NCT ID: NCT01222013 Suspended - Clinical trials for Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)

Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, through molecular response and event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM "like" Induction in children with ALL Ph+.

NCT ID: NCT01221376 Active, not recruiting - Clinical trials for Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

NCT ID: NCT01220648 Completed - Clinical trials for Chronic Myeloid Leukemia

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

NICOLI
Start date: April 2012
Phase: Phase 1
Study type: Interventional

This study will assess the maximum tolerated dose of low dose interferon in conjunction with nilotinib in pretreated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP).

NCT ID: NCT01066468 Terminated - Clinical trials for Chronic Myeloid Leukemia (CML)

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens